Osteoclast activity modulates B-cell development in the bone marrow

Cell Research

Volumn 21, Issue 7, 2011, Pages 1102-1115

  Mansour, Anna ^a,b   Anginot, Adrienne ^c,d   Mancini, Stéphane J C ^c,d   Schiff, Claudine ^c,d   Carle, Georges F ^a,b   Wakkach, Abdelilah ^a,b,e   Blin Wakkach, Claudine ^a,b,e  

^a CNRS   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

B cells; hematopoietic niche; osteoclast; osteopetrosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; INTERLEUKIN 7; STROMAL CELL DERIVED FACTOR 1; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; ANIMAL; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; BONE; BONE MARROW; BONE MARROW CELL; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DRUG EFFECT; FEMALE; LYMPHOPOIESIS; METABOLISM; MOUSE; OSTEOCLAST; STROMA CELL;

ANIMALS; B-LYMPHOCYTES; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE MARROW; BONE MARROW CELLS; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL12; DIPHOSPHONATES; FEMALE; IMIDAZOLES; INTERLEUKIN-7; LYMPHOPOIESIS; MICE; MICE, INBRED BALB C; OSTEOCLASTS; OSTEOPETROSIS; STROMAL CELLS;

MUS;

EID: 79960126547     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2011.21     Document Type: Article

References (53)

1. Walsh MC, Kim N, Kadono Y, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006; 24:33-63.
2. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425:836-841. (Pubitemid 37351467)
3. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425:841-846. (Pubitemid 37351468)
4. Visnjic D, Kalajzic Z, Rowe DW, et al. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 2004; 103:3258-3264. (Pubitemid 38525648)
5. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004; 20:707-718. (Pubitemid 38757441)
6. Wu JY, Purton LE, Rodda SJ, et al. Osteoblastic regulation of B lymphopoiesis is mediated by Gs{alpha}-dependent sig naling pathways. Proc Natl Acad Sci USA 2008; 105:16976-16981.
7. Hardy RR, Carmack CE, Shinton SA, Kemp JD, Hayakawa K. Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. J Exp Med 1991; 173:1213-1225.
8. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol 2001; 19:595-621. (Pubitemid 32368047)
9. Zhu J, Garrett R, Jung Y, et al. Osteoblasts support B-lymphocyte commitment and differentiation from hematopoietic stem cells. Blood 2007; 109:3706-3712. (Pubitemid 46641719)
10. Nagasawa T, Hirota S, Tachibana K, et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996; 382:635-638. (Pubitemid 26268957)
11. Ma Q, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999; 10:463-471. (Pubitemid 29205482)
12. Egawa T, Kawabata K, Kawamoto H, et al. The earliest stages of B cell development require a chemokine stromal cellderived factor/pre-B cell growth-stimulating factor. Immunity 2001; 15:323-334. (Pubitemid 32816880)
13. von Freeden-Jeffry U, Vieira P, Lucian LA, et al. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995; 181:1519-1526.
14. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412-2424. (Pubitemid 29453612)
15. Franzoso G, Carlson L, Xing L, et al. Requirement for NFkappaB in osteoclast and B-cell development. Genes Dev 1997; 11:3482-3496. (Pubitemid 28023969)
16. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymphnode organogenesis. Nature 1999; 397:315-323.
17. Naito A, Azuma S, Tanaka S, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999; 4:353-362. (Pubitemid 29359450)
18. Tagaya H, Kunisada T, Yamazaki H, et al. Intramedullary and extramedullary B lymphopoiesis in osteopetrotic mice. Blood 2000; 95:3363-3370. (Pubitemid 30428465)
19. Yoshida H, Hayashi S, Kunisada T, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345:442-444. (Pubitemid 120014957)
20. Blin-Wakkach C, Wakkach A, Sexton PM, Rochet N, Carle GF. Hematological defects in the oc/oc mouse, a model of infantile malignant osteopetrosis. Leukemia 2004; 18:1505-1511. (Pubitemid 39264073)
21. Scimeca JC, Franchi A, Trojani C, et al. The gene encoding the mouse homologue of the human osteoclast-specific 116- kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/ oc) mutants. Bone 2000; 26:207-213. (Pubitemid 30101642)
22. Blin-Wakkach C, Wakkach A, Rochet N, Carle GF. Characterization of a novel bipotent hematopoietic progenitor population in normal and osteopetrotic mouse. J Bone Miner Res 2004; 7:1137-1143. (Pubitemid 41110566)
23. Blin-Wakkach C, Wakkach A, Quincey D, Carle GF. Interleukin- 7 partially rescues B-lymphopoiesis in osteopetrotic oc/oc mice through the engagement of B220(+)CD11b(+) progenitors. Exp Hematol 2006; 34:851-859. (Pubitemid 43949185)
24. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008; 19:733-759.
25. Hornby SB, Evans GP, Hornby SL, et al. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int 2003; 72:519-527. (Pubitemid 36919519)
26. Herrak P, Gortz B, Hayer S, et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factormediated arthritis. Arthritis Rheum 2004; 50:2327-2337. (Pubitemid 38924413)
27. Corso A, Ferretti E, Lunghi M, et al. Zoledronic acid downregulates adhesion molecules of bone marrow stromal cells in multiple myeloma. A possible mechanism for its antitumor effect. Cancer 2005; 104:118-125. (Pubitemid 40847759)
28. Guenther A, Gordon S, Tiemann M, et al. The bisphosphonate zoledronic acid has anti-myeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010; 126:239-246.
29. Wakkach A, Mansour A, Dacquin R, et al. Bone marrow microenvironment controls the in vivo differentiation of murine dendritic cells into osteoclasts. Blood 2008; 112:5074-5083.
30. Frattini A, Blair HC, Sacco MG, et al. Rescue of ATPa3-deficient murine malignant osteopetrosis by hematopoietic stem cell transplantation in utero. Proc Natl Acad Sci USA 2005; 102:14629-14634. (Pubitemid 41457107)
31. Johansson M, Jansson L, Ehinger M, et al. Neonatal hematopoietic stem cell transplantation cures oc/oc mice from osteopetrosis. Exp Hematol 2006; 34:242-249. (Pubitemid 43184329)
32. Whyte MP, McAlister WH, Novack DV, et al. Bisphosphonate- induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res 2008; 23:1698-1707.
33. Inlay MA, Bhattacharya D, Sahoo D, et al. Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. Genes Dev 2009; 23:2376-2381.
34. Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K. Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res 2007; 22:487-494. (Pubitemid 47457424)
35. Matsuo K, Irie N. Osteoclast-osteoblast communication. Arch Biochem Biophys 2008; 473:201-209.
36. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/ Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89:747-754. (Pubitemid 27516177)
37. van Beek E, Lowik C, Van der Pluijm G, Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999; 14:722-729. (Pubitemid 29210598)
38. Coxon FP, Helfrich MH, vant Hof RJ, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000; 15:1467-1476. (Pubitemid 30484516)
39. Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003; 9:2643-2658. (Pubitemid 37456015)
40. Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clini cal efficacy. Ann N Y Acad Sci 2007; 1117:209-257. (Pubitemid 350191297)
41. Sims NA, Green JR, Glatt M, et al. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum 2004; 50:2338-2346. (Pubitemid 38924414)
42. Colucci S, Minielli V, Zambonin G, et al. Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif Tissue Int 1998; 63:230-235. (Pubitemid 28387975)
43. Seifert MF, Marks SC, Jr. Morphological evidence of reduced bone resorption in the osteosclerotic (oc) mouse. Am J Anat 1985; 172:141-153. (Pubitemid 15117245)
44. Peschon JJ, Morrissey PJ, Grabstein KH, et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptordeficient mice. J Exp Med 1994; 180:1955-1960.
45. Kawabata K, Ujikawa M, Egawa T, et al. A cell-autonomous requirement for CXCR4 in long-term lymphoid and myeloid reconstitution. Proc Natl Acad Sci USA 1999; 96:5663-5667. (Pubitemid 29234675)
46. Tauchmanova L, Ricci P, Serio B, et al. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2005; 90:627-634. (Pubitemid 40279172)
47. von Knoch F, Jaquiery C, Kowalsky M, et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005; 26:6941-6949. (Pubitemid 41095518)
48. Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008; 23:6-16.
49. Orriss IR, Key ML, Colston KW, Arnett TR. Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 2009; 106:109-118.
50. Schindeler A, Little DG. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. Biochem Biophys Res Commun 2005; 338:710-716. (Pubitemid 41597701)
51. Malaval L, Wade-Guéye NM, Boudiffa M, et al. Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med 2008; 205:1145-1153. (Pubitemid 351679689)
52. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001; 25:402-408. (Pubitemid 34164012)
53. Kuznetsov SA, Krebsbach PH, Satomura K, et al. Singlecolony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. J Bone Miner Res 1997; 12:1335-1347. (Pubitemid 27375376)